Epidemiology of non-steroidal anti-inflammatory drugs and cancer

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 1-24

  Baron, John A ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST TUMOR; CLINICAL TRIAL; ESOPHAGUS TUMOR; FEMALE; HUMAN; MALE; NEOPLASM; OVARY TUMOR; PANCREAS TUMOR; PROSTATE TUMOR; REVIEW; STOMACH TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 0042131693     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071364     Document Type: Article

References (97)

1. Macfarlane GJ, Black RJ: Rheumatoid arthritis and lymphatic cancer. Eur J Cancer 1996;32A:1630-1632.
2. Thomas E, Brewster DH, Black RJ, Macfarlane GJ: Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
3. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
4. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77:219-225.
5. Hakulinen T, Isomaki H, Knekt P: Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29-32.
6. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311.
7. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH: Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-1757.
8. Kauppi M, Pukkala E, Isomaki H: Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996;14:551-553.
9. Cibere J, Sibley J, Haga M: Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-1586.
10. Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E: Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985;78:50-55.
11. Muller AD, Sonnenberg A, Wasserman IH: Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 1994;39:2480-2484.
12. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications: Case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-4404.
13. Garcia Rodriguez LA, Huerta-Alvarez C: Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs: A pooled analysis of published studies and a new population-based study. Epidemiology 2000;11:376-381.
14. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF Jr: Prior medical conditions and the risk of adult leukemia in Shanghai, PR China. Cancer Causes Control 1993;4:361-368.
15. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-358.
16. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
17. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-1327.
18. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121:241-246.
19. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L: Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing. Br J Cancer 1999;81:62-68.
20. Garcia-Rodriguez LA, Huerta-Alvarez C: Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12:88-93.
21. Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer 1993;72:171-1177.
22. Rosenberg L, Rao RS, Palmer JR, Strom BL, Zauber A, Warshauer ME, Stolley PD, Shapiro S: Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 1998;9:83-88.
23. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG: The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Preventive Medicine 1999; 29:72-76.
24. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini A, Decarli A: Aspirin and colorectal cancer. Br J Cancer 1997;76:675-677.
25. Smalley W, Ray WA, Daugherty J, Griffin MR: Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study. Arch Intern Med 1999;159:61-166.
26. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: A cohort study of the elderly. BMJ 1989;299:1247-1250.
27. Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and incidence of large-bowel cancer in a California retirement community. Journal of the National Cancer Institute 1991;83:182-1183.
28. Rosenberg L, Louik C, Shapiro S: Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998;82:2326-2333.
29. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL: Nonsteroidal antiinflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-960.
30. Peleg II, Maibach HT, Brown SH, Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer Arch Intern Med 1994;154:394-399.
31. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-146.
32. Peleg I, Lubin M, Cotsonis G, Clark W, Wilcox C: Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319-1326.
33. Muscat JE, Stellman SD, Wynder EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994;74:1847-1854.
34. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000;320:1642-1646.
35. Meier CR, Schmitz S, Jick H: Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002;22:303-309.
36. Friedman G, Coates A, Potter J, Slattery M: Drugs and colon cancer. Pharmacoepidemiol Drug Saf 1998;7:99-106.
37. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:12-916.
38. Logan R, Little J, Hawtin P, Hardcastel J: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in Nottingham faecal occult blood screening programme. BMJ 1993;307:285-289.
39. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, Goebell H: Longterm use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-134.
40. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT: Aspirin and nonsteroidal antiinflammatory agents and risk for colorectal adenomas. Gastroenterology 1998;114:441-447.
41. Martinez ME, McPherson RS, Levin B, Annegers JF: Aspirin and other nonsteroidal antiinflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995;4:703-707.
42. Rex DK, Cummings OW, Helper DJ, Nowak TV, McGill JM, Chiao GZ, Kwo PY, Gottlieb KT, Ikenberry SO, Gress FG, Lehman GA, Born LJ: Five-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons. Gastroenterology 1996;111:1178-1181.
43. Rodriguez C, Henley SJ, Calle EE, Thun MJ: Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet 1998;352:1354-1355.
44. Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD: Risk factors for advanced colorectal adenomas: A pooled analysis. Cancer Epidemiol Biomarkers Prev 2002;11:622-629.
45. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO: Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117-120.
46. Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-1183.
47. Lindberg BU, Broome U, Persson B: Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: Results from a 20-year surveillance study. Dis Colon Rectum 2001;44:77-85.
48. Bansal P, Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-48.
49. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
50. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
51. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619.
52. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-954.
53. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H: The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: Clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993;8:13-17.
54. Hirota C, Iida M, Aoyagi K, Matsumoto T, Tada S, Yao T, Fujishima M: Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996; 78:1660-1665.
55. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE: NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88:1652-1656.
56. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T: Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40:344-349.
57. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB: Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-1087.
58. DiSario J, Alberts D, Tietze C, Khullar S, Bohman V, Larsen B, Hixson L, Samowitz W, Reading J, Buys S, Dawson R, Burt R: Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastroenterology 1996;112:A555.
59. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-1224.
60. Funkhouser EM, Sharp GB: Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:116-1119.
61. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
62. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S: Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-123.
63. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O: Aspirin and risk for gastric cancer: A population-based case-control study in Sweden. Br J Cancer 2001;84:965-968.
64. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V: Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia. Int J Cancer 1999;82:473-476.
65. Anderson KE, Johnson TW, Lazovich D, Folsom AR: Association between nonsteroidal antiinflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-1171.
66. Harris RE, Kasbari S, Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999;6:71-73.
67. Harris RE, Namboodiri KK, Stellman SD, Wynder EL: Breast cancer and NSAID use: Heterogeneity of effect in a case-control study. Prev Med 1995;24:119-120.
68. Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996;7:203-205.
69. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000;83:112-120.
70. Cotterchio M, Kreiger N, Sloan M, Steingart A: Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-1217.
71. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-993.
72. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S: A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933-937.
73. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER: Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998;351:104-107.
74. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE: Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002;13:535-542.
75. Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D: Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993;55:408-410.
76. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H: Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:903-906.
77. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S: Aspirin and ovarian cancer: An Italian case-control study. Ann Oncol 2000;11:1171-1173.
78. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82:1364-1369.
79. Kaye JA, Myers MW, Jick H: Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 2001;12:690-694.
80. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M: Urothelial cancer at different tumour sites: Role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999;14:2892-2897.
81. McLaughlin JK, Blot WJ, Mehl ES, Fraumeni JF Jr: Relation of analgesic use to renal cancer: Population-based findings. Natl Cancer Inst Monogr 1985;69:217-222.
82. McCredie M, Ford JM, Stewart JH: Risk factors for cancer of the renal parenchyma. Int J Cancer 1988;42:13-16.
83. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC: Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999;81:542-548.
84. Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Cherng N: Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis and conclusions. Cancer Detect Prev 1988;13:263-279.
85. McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P, Mandel JS, Mellemgaard A, Schlehofer B, Niwa S: International renal-cell cancer study. II. Analgesics. Int J Cancer 1995;60:45-349.
86. McCredie M, Stewart JH, Day NE: Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993;53:245-249.
87. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE: Analgesics, cigarette smoking and other risk factors for cancer of the renal pelvis and ureter. Cancer Res 1989;49:1045-1048.
88. Jensen OM, Knudsen JB, Tomasson H, Sorensen BL: The Copenhagen case-control study of renal pelvis and ureter cancer: Role of analgesics. Int J Cancer 1989;44:965-968.
89. Linet MS, Chow WH, McLaughlin JK, Wacholder S, Yu MC, Schoenberg JB, Lynch C, Fraumeni JF Jr: Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 1995;62:15-18.
90. Norrish AE, Jackson RT, McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-515.
91. Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs: Results of a case-control study. Oncol Rep 2000;7:169-170.
92. Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002;13:427-434.
93. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S: Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J Clin Res Ed 1988;296:313-316.
94. Harris RE, Beebe-Donk J, Namboodiri KK: Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001;8:655-657.
95. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM: Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769-781.
96. Suleiman S, Rex DK, Sonnenberg A: Chemoprevention of colorectal cancer by aspirin: A costeffectiveness analysis. Gastroenterology 2002;122:78-84.
97. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE: Aspirin and epithelial ovarian cancer. Prev Med 2001;33:682-768.